Every material Form 8-K Valion Bio, Inc. has filed with the SEC since October 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
Registration statement to be filed within 30 days after closing and declared effective within 60 days
Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Valion Bio, Inc. disclosed that Lisa Wolf, its President, Chief Operating Officer and Chief Financial Officer, has voluntarily resigned from all three roles, with the resignation effective December 11, 2026. The filing does not state a reason or name a successor, so shareholders will need to watch for a replacement announcement.
Lisa Wolf notified the Special Committee of the Board on October 31, 2026.
Her resignation covers the positions of President, Chief Operating Officer and Chief Financial Officer.
The resignation takes effect December 11, 2026, and had not yet taken effect as of the filing date.
Valion Bio, Inc. terminated General Counsel and Senior Vice President of Legal Affairs Melinda Lackey, effective October 30, 2026, under a separation agreement signed October 31, 2026. The filing also reports that the Armed Forces Radiobiology Research Institute will evaluate the therapeutic efficacy of the company's lead candidate, Entolimod, with top-line results anticipated in early December.
Lackey was notified of her termination on October 27, 2026, effective October 30, 2026.
Severance is a $26,750 gross lump-sum payment, due no later than 30 days after the agreement's effective date, plus possible COBRA premium payments through November 30, 2026.
Lackey forfeits unvested equity awards; vested stock options may be exercised only under the equity plan documents.
The NIAID-funded study will test whether Entolimod given 24 hours after radiation exposure improves survival; top-line results are expected in early December.
Valion Bio said the Armed Forces Radiobiology Research Institute found no evidence of treatment-related toxicity after a single dose of its lead candidate, Entolimod, in a 14-day mouse study. The company said the result supports moving toward a planned therapeutic study on survival and gastrointestinal recovery after radiation exposure, which it expects to be fully funded.
Study of 20 male C57BL/6 mice evaluated a single subcutaneous Entolimod dose at 0.72 mg/kg against a saline control, with a 14-day observation period
Body weight showed no statistically significant overall difference from control (p = 0.1424); blood counts stayed within normal reference ranges; serum chemistry showed normal organ and metabolic function
Next step is an AFRRI therapeutic study testing whether Entolimod given after radiation exposure improves survival and GI tissue recovery; no start date was given
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Valion Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →